[EN] OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF [FR] DÉRIVÉ D'OXADIAZOLE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION [ZH] 一种噁二唑衍生物及其制备方法和用途
[EN] OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF [FR] DÉRIVÉ D'OXADIAZOLE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION [ZH] 一种噁二唑衍生物及其制备方法和用途
[EN] HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS<br/>[FR] AMIDES DE CHROMÈNE HÉTÉROCYCLIQUE-PIPÉRIDINE SPIROCYCLIQUE UTILES COMME MODULATEURS DES CANAUX IONIQUES
申请人:VERTEX PHARMA
公开号:WO2011140425A1
公开(公告)日:2011-11-10
The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
[EN] BENZOXAZINES AS MODULATORS OF ION CHANNELS<br/>[FR] BENZOXAZINES COMME MODULATEURS DES CANAUX IONIQUES
申请人:VERTEX PHARMA
公开号:WO2013067248A1
公开(公告)日:2013-05-10
The invention relates to benzoxazines useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
The present disclosure relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine-1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acceptable salts thereof.
The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.
HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
申请人:Hadida-Ruah Sara Sabina
公开号:US20110306607A1
公开(公告)日:2011-12-15
The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.